98%
921
2 minutes
20
In invertebrates, UNC-45 regulates myosin stability and functions. Vertebrates have two distinct isoforms of the protein: UNC-45B, expressed in muscle cells only, and UNC-45A, expressed in all cells and implicated in regulating both non-muscle myosin II (NMII)- and microtubule (MT)-associated functions. Here, we show that, and in human and rat cells, UNC-45A binds to the MT lattice, leading to MT bending, breakage and depolymerization. Furthermore, we show that UNC-45A destabilizes MTs independent of its C-terminal NMII-binding domain and even in the presence of the NMII inhibitor blebbistatin. These findings identified UNC-45A as a novel type of MT-severing protein with a dual non-mutually exclusive role in regulating NMII activity and MT stability. Because many human diseases, from cancer to neurodegenerative diseases, are caused by or associated with deregulation of MT stability, our findings have profound implications in the biology of MTs, as well as the biology of human diseases and possible therapeutic implications for their treatment.This article has an associated First Person interview with the joint first authors of the paper.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803465 | PMC |
http://dx.doi.org/10.1242/jcs.248815 | DOI Listing |
Sci Rep
September 2025
Departamento de Genética, Fisiología y Microbiología, Facultad de Ciencias Biológicas, Universidad Complutense de Madrid, Madrid, 28040, Spain.
The remodeling of epithelial tissues is a critical process in morphogenesis, often involving the apoptotic removal of individual cells while preserving tissue integrity. In Drosophila, the amnioserosa-a highly dynamic extra-embryonic tissue-undergoes extensive remodeling, culminating in its complete elimination at the end of dorsal closure. While apoptotic cell delaminations in the amnioserosa have been proposed to contribute to dorsal closure, the cellular mechanisms underlying this process remain poorly understood.
View Article and Find Full Text PDFCell
August 2025
Departments of Cell Biology, Physiology, Pharmacology, and Therapeutics, Medicine, Oncology, and Chemical and Biomolecular Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. Electronic address:
In this issue of Cell, Kenchappa et al. and Radnai et al. report the development of selective non-muscle myosin II inhibitors that show therapeutic potential in glioblastoma and methamphetamine use disorder, opening new avenues for targeting cell mechanobiology in challenging diseases.
View Article and Find Full Text PDFMol Biol Cell
August 2025
Department of Biological Sciences, University of Delaware, Newark, Delaware, USA.
The mouse ocular lens is an excellent vertebrate model for epithelial cell hexagonal packing during tissue morphogenesis. As lens epithelial cells differentiate into fiber cells, the epithelial cells rearrange into hexagonally packed meridional row (MR) cells that further differentiate to form fiber cells. We previously reported that the nonmuscle myosin IIA (NMIIA)-E1841K mutation, which alters NMIIA bipolar filament assembly, significantly disrupts MR cell hexagonal packing.
View Article and Find Full Text PDFEur J Med Chem
December 2025
HUN-REN-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, H-1117, Budapest, Hungary; Motorpharma Ltd., Batthyány utca 54, H-1015, Budapest, Hungary. Electronic address:
There is a long-standing need for inhibitors that selectively target the actomyosin complex, the terminal effector of diverse processes that involve movement in the cells or the body. Such compounds, we term as actomyolytics, hold promise for treating numerous conditions with minimum adverse effects. In this study, we developed efficient synthesis pathways and conducted a detailed structure-activity relationship (SAR) analysis of 144 potential actomyolytics (referred to as the MPH-family) targeting the blebbistatin binding site on myosin-2.
View Article and Find Full Text PDFFront Pediatr
July 2025
Department of Clinical Laboratory, Handan Central Hospital, Handan, China.
Introduction: MYH9-related disease (MYH9-RD) is a rare autosomal dominant genetic syndrome characterized by congenital thrombocytopenia, with a risk of developing progressive nephropathy, sensorineural deafness, and presenile cataract. Due to its presentation of isolated thrombocytopenia, it is frequently misdiagnosed as immune thrombocytopenic purpura (ITP).
Methods: A 10-year-old girl with an initial diagnosis of ITP was evaluated, based on isolated thrombocytopenia and intermittent epistaxis.